Free tool
FAERS Monitor: Keveyis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011366 or its brand name (Keveyis, Dichlorphenamide). Reports on generic versions are filed under their own applications.
Reports
1,646
Serious
461
28% of reports
Hospitalization
253
Death reported
13
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- paraesthesia304
- fatigue231
- disease recurrence173
- muscular weakness165
- feeling abnormal162
- wrong technique in product usage process151
- asthenia145
- confusional state129
- dizziness119
- nausea117
- headache102
- blood potassium decreased97
- dysgeusia93
- malaise92
- condition aggravated91
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2015 | 9 |
| 2016 | 37 |
| 2017 | 158 |
| 2018 | 313 |
| 2019 | 261 |
| 2020 | 295 |
| 2021 | 348 |
| 2022 | 33 |
| 2023 | 38 |
| 2024 | 63 |
| 2025 | 55 |
| 2026 | 35 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,513 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease recurrenceSignal | 173 | 46.6 | 40.5 | 7,669 |
| blood potassium decreasedSignal | 97 | 41.4 | 34.1 | 3,773 |
| paraesthesiaSignal | 304 | 24.7 | 22.3 | 6,939 |
| muscular weaknessSignal | 165 | 18.6 | 16.1 | 2,737 |
| dysgeusiaSignal | 93 | 16.0 | 13.1 | 1,297 |
| confusional stateSignal | 129 | 10.2 | 8.6 | 1,070 |
| wrong technique in product usage processSignal | 151 | 9.5 | 8.2 | 1,154 |
| feeling abnormalSignal | 162 | 8.6 | 7.5 | 1,099 |
| astheniaSignal | 145 | 4.9 | 4.2 | 458 |
| condition aggravatedSignal | 91 | 3.8 | 3.1 | 190 |
| fatigueSignal | 231 | 3.8 | 3.4 | 490 |
| dizzinessSignal | 119 | 3.0 | 2.6 | 166 |
| malaiseSignal | 92 | 2.7 | 2.2 | 97 |
| headacheSignal | 102 | 2.1 | 1.7 | 58 |
| nausea | 117 | 1.9 | 1.6 | 50 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.